IP Library › Granted Patent US 12,678,406
Granted Patent B2
US 12,678,406 · App. 17/450,628 · Granted Jul 14, 2026

Process of preparing ice-based lipid nanoparticles

Inventors: Monic Shah (Lexington, MA); Travis Jeannotte (Lexington, MA); Yi Zhang (Lexington, MA); Shrirang Karve (Lexington, MA); Kimberly Gillis (Lexington, MA); Frank DeRosa (Lexington, MA)
Assignee: TRANSLATE BIO INC.
A61K9/1272A61K9/1277A61K31/7105
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,678,406
App. No.
17/450,628
Filed
Oct 12, 2021
Granted
Jul 14, 2026
Kind
B2
Art Unit
1612
USPC
424/450
Abstract

The present invention provides an improved process for lipid nanoparticle formulation and mRNA encapsulation. In some embodiments, the present invention provides a process of encapsulating messenger RNA (mRNA) in lipid nanoparticles comprising a step of mixing an mRNA solution containing low citrate concentration and a lipid solution at an ambient temperature. Thus, the present invention provides an effective, reliable, energy-saving and cost-effective method of encapsulating mRNA into lipid nanoparticles.

Claims (20)

1 . A process of encapsulating messenger RNA (mRNA) in lipid nanoparticles (LNPs) comprising a step of mixing (a) an mRNA solution comprising one or more mRNAs with (b) a lipid solution comprising one or more cationic lipids, one or more non-cationic lipids, and one or more PEG-modified lipids, to form mRNA encapsulated within the LNPs (mRNA-LNPs) in a LNP formation solution, wherein the mRNA solution comprises less than 5 mM of citrate, wherein the lipid solution comprises imidazole cholesterol ester (ICE), and wherein the mRNA-LNPs have an average size less than 80 nm, and wherein the encapsulation efficiency of the mRNA-LNPs is greater than about 60%.

2 . The process of claim 1 , wherein the mRNA solution and/or the lipid solution are at an ambient temperature prior to mixing, and wherein the ambient temperature is less than about 35° C., less than about 30° C., less than about 26° C., less than about 23° C., less than about 21° C., less than about 20° C., or less than about 18° C.

3 . The process of claim 1 , wherein the mRNA solution comprises less than about 4.0 mM of citrate, less than about 3.0 mM of citrate, less than about 2.5 mM of citrate, less than about 2.0 mM of citrate, less than about 1.5 mM of citrate, less than about 1.25 mM of citrate, less than about 1.0 mM of citrate, or less than about 0.5 mM of citrate.

4 . The process of claim 1 , wherein the mRNA-LNPs have an average size less than 70 nm, less than 60 nm, less than 50 nm, or less than 40 nm.

5 . The process of claim 1 , wherein the encapsulation efficiency of the mRNA-LNPs is greater than about 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, or 99%.

6 . The process of claim 1 , wherein the mRNA-LNPs have an N/P ratio of between 1 to 10.

7 . The process of claim 1 , wherein the mRNA solution further comprises trehalose.

8 . The process of claim 1 , wherein the process does not require a step of heating the mRNA solution and the lipid solution prior to the mixing step.

9 . The process of claim 1 , wherein the mRNA solution and the lipid solution are mixed at a ratio (v/v) of between 2:1 and 6:1.

10 . The process of claim 1 , wherein the mRNA solution has a pH between 3.0 and 5.0.

11 . The process of claim 1 , wherein the mRNA solution comprises about 37.5 mM to 300 mM NaCl.

12 . The process of claim 1 , wherein the mRNA solution comprises about 2.5 mM citrate, about 150 mM NaCl, and pH of about 4.5.

13 . The process of claim 1 , wherein the process further comprises a step of incubating the mRNA-LNPs.

14 . The process of claim 1 , wherein the lipid solution comprises less than 50%, less than 25%, less than 20%, less than 10%, or less than 5% non-aqueous solvent.

15 . The process of claim 1 , wherein the lipid solution further comprises one or more additional cholesterol-based lipids.

16 . A composition comprising mRNA encapsulated in lipid nanoparticles prepared by the process of claim 1 .

17 . The composition of claim 16 , wherein the mRNA comprises one or more modified nucleotides.

18 . The process of claim 1 , wherein the mRNA-LNP average size is at least 5 nm smaller compared to an mRNA-LNP formed from the mRNA solution mixed with the lipid solution under the same conditions except with the mRNA solution having 10 mM citrate.

19 . A process of encapsulating messenger RNA (mRNA) in lipid nanoparticles (LNPs) comprising a step of mixing (a) an mRNA solution comprising one or more mRNAs with (b) a lipid solution comprising one or more cationic lipids, one or more non-cationic lipids, and one or more PEG-modified lipids, to form mRNA encapsulated within the LNPs (mRNA-LNPs) in a LNP formation solution, wherein the mRNA solution comprises between 0.1 mM and 5 mM citrate, wherein the lipid solution comprises imidazole cholesterol ester (ICE), wherein the mRNA-LNPs have an average size less than 80 nm, and wherein the encapsulation efficiency of the mRNA-LNPs is greater than about 60%.

20 . The process of claim 19 , wherein the mRNA solution comprises between about 1 mM and 4 mM citrate.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2024
From: TRANSLATE BIO MA, INC.
To: TRANSLATE BIO, INC.
Reel/Frame 066064/0933 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 9, 2024
From: SHAH, MONIC; JEANNOTTE, TRAVIS; ZHANG, YI; KARVE, SHRIRANG; GILLIS, KIMBERLY; DEROSA, FRANK
To: TRANSLATE BIO MA, INC.
Reel/Frame 066064/0893 →
Continuity (2)
Provisional Application 63090509 · Oct 12, 2020
Related Publication 20220133631A1 · May 5, 2022
References Cited (281)
US 4857319A · Crowe et al. · 1989 [cited by applicant]
US 5049392A · Weiner et al. · 1991 [cited by applicant]
US 5605251A · Retti et al. · 1997 [cited by applicant]
US 5705385A · Bally et al. · 1998 [cited by applicant]
US 5948441A · Lenck et al. · 1999 [cited by applicant]
US 5976567A · Wheeler · 1999 [cited by applicant]
US 5981501A · Wheeler et al. · 1999 [cited by applicant]
US 6534484B1 · Wheeler et al. · 2003 [cited by applicant]
US 6815432B2 · Wheeler et al. · 2004 [cited by applicant]
US 6855296B1 · Baker et al. · 2005 [cited by applicant]
US 7094423B1 · Maurer et al. · 2006 [cited by applicant]
US 7422902B1 · Wheeler et al. · 2008 [cited by applicant]
US 7745651B2 · Heyes et al. · 2010 [cited by applicant]
US 7799565B2 · MacLachlan et al. · 2010 [cited by applicant]
US 7803397B2 · Heyes et al. · 2010 [cited by applicant]
US 7901708B2 · MacLachlan et al. · 2011 [cited by applicant]
US 8101741B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8188263B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8236943B2 · Lee et al. · 2012 [cited by applicant]
US 8329070B2 · MacLachlan et al. · 2012 [cited by applicant]
US 8513403B2 · MacLachlan et al. · 2013 [cited by applicant]
US 8569256B2 · Heyes et al. · 2013 [cited by applicant]
US 8710200B2 · Schrum et al. · 2014 [cited by applicant]
US 8822663B2 · Schrum et al. · 2014 [cited by applicant]
US 8853377B2 · Guild et al. · 2014 [cited by applicant]
US 8883202B2 · Manoharan et al. · 2014 [cited by applicant]
US 8936942B2 · Heyes et al. · 2015 [cited by applicant]
US 8980864B2 · Hoge et al. · 2015 [cited by applicant]
US 8999351B2 · Manoharan et al. · 2015 [cited by applicant]
US 8999950B2 · MacLachlan et al. · 2015 [cited by applicant]
US 9018187B2 · Heyes et al. · 2015 [cited by applicant]
US 9051567B2 · Fitzgerald et al. · 2015 [cited by applicant]
US 9061059B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9074208B2 · MacLachlan et al. · 2015 [cited by applicant]
US 9089604B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9095552B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9107886B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9114113B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9181319B2 · Schrum et al. · 2015 [cited by applicant]
US 9186325B2 · Manoharan et al. · 2015 [cited by applicant]
US 9186372B2 · de Fougerolles et al. · 2015 [cited by applicant]
US 9187748B2 · Geisbert et al. · 2015 [cited by applicant]
US 9192651B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9220755B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9220792B2 · Chakraborty et al. · 2015 [cited by applicant]
US 9233141B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9254311B2 · Bancel et al. · 2016 [cited by applicant]
US 9295689B2 · De Fougerolles et al. · 2016 [cited by applicant]
US 9301993B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9303079B2 · Chakraborty et al. · 2016 [cited by applicant]
US 9334328B2 · Schrum et al. · 2016 [cited by applicant]
US 9345780B2 · Manoharan et al. · 2016 [cited by applicant]
US 9352042B2 · Heyes et al. · 2016 [cited by applicant]
US 9352048B2 · Manoharan et al. · 2016 [cited by applicant]
US 9364435B2 · Yaworski et al. · 2016 [cited by applicant]
US 9668980B2 · DeRosa et al. · 2017 [cited by applicant]
US 20020192651A1 · Wheeler et al. · 2002 [cited by applicant]
US 20030181410A1 · Wheeler et al. · 2003 [cited by applicant]
US 20040142025A1 · MacLachlan et al. · 2004 [cited by applicant]
US 20060008910A1 · MacLachlan et al. · 2006 [cited by applicant]
US 20060083780A1 · Heyes et al. · 2006 [cited by applicant]
US 20070042031A1 · MacLachlan et al. · 2007 [cited by applicant]
US 20070135372A1 · MacLachlan et al. · 2007 [cited by applicant]
US 20090270481A1 · MacLachlan et al. · 2009 [cited by applicant]
US 20100041152A1 · Wheeler et al. · 2010 [cited by applicant]
US 20100323356A1 · Inoue et al. · 2010 [cited by applicant]
US 20110200582A1 · Baryza et al. · 2011 [cited by applicant]
US 20110244026A1 · Guild · 2011 [cited by examiner]
US 20110256175A1 · Hope et al. · 2011 [cited by applicant]
US 20110311583A1 · Manoharan et al. · 2011 [cited by applicant]
US 20120065252A1 · Schrum et al. · 2012 [cited by applicant]
US 20120128760A1 · Manoharan et al. · 2012 [cited by applicant]
US 20120142756A1 · Guild et al. · 2012 [cited by applicant]
US 20120202871A1 · Heyes et al. · 2012 [cited by applicant]
US 20120237975A1 · Schrum et al. · 2012 [cited by applicant]
US 20120251618A1 · Schrum et al. · 2012 [cited by applicant]
US 20120276209A1 · Cullis et al. · 2012 [cited by applicant]
US 20120295832A1 · Constien et al. · 2012 [cited by applicant]
US 20120328668A1 · MacLachlan et al. · 2012 [cited by applicant]
US 20130017223A1 · Hope et al. · 2013 [cited by applicant]
US 20130037977A1 · Burke et al. · 2013 [cited by applicant]
US 20130115274A1 · Knopov et al. · 2013 [cited by applicant]
US 20130156849A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130195967A1 · Guild et al. · 2013 [cited by applicant]
US 20130237594A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20130259923A1 · Bancel et al. · 2013 [cited by applicant]
US 20130259924A1 · Bancel et al. · 2013 [cited by applicant]
US 20130266640A1 · de Fougerolles et al. · 2013 [cited by applicant]
US 20140010861A1 · Bancel et al. · 2014 [cited by applicant]
US 20140044772A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140105964A1 · Bancel et al. · 2014 [cited by applicant]
US 20140105965A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147432A1 · Bancel et al. · 2014 [cited by applicant]
US 20140147454A1 · Chakraborty et al. · 2014 [cited by applicant]
US 20140148502A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155472A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155473A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155474A1 · Bancel et al. · 2014 [cited by applicant]
US 20140155475A1 · Bancel et al. · 2014 [cited by applicant]
US 20140171485A1 · Bancel et al. · 2014 [cited by applicant]
US 20140179756A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140179771A1 · Bancel et al. · 2014 [cited by applicant]
US 20140186432A1 · Bancel et al. · 2014 [cited by applicant]
US 20140193482A1 · Bancel et al. · 2014 [cited by applicant]
US 20140194494A1 · Bancel et al. · 2014 [cited by applicant]
US 20140199371A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200261A1 · Hoge et al. · 2014 [cited by applicant]
US 20140200262A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200263A1 · Bancel et al. · 2014 [cited by applicant]
US 20140200264A1 · Bancel et al. · 2014 [cited by applicant]
US 20140206752A1 · Afeyan et al. · 2014 [cited by applicant]
US 20140206753A1 · Guild et al. · 2014 [cited by applicant]
US 20140206755A1 · Bancel et al. · 2014 [cited by applicant]
US 20140206852A1 · Hoge et al. · 2014 [cited by applicant]
US 20140221465A1 · Bancel et al. · 2014 [cited by applicant]
US 20140243399A1 · Schrum et al. · 2014 [cited by applicant]
US 20140249208A1 · Bancel et al. · 2014 [cited by applicant]
US 20140255467A1 · Bancel et al. · 2014 [cited by applicant]
US 20140255468A1 · Bancel et al. · 2014 [cited by applicant]
US 20140275227A1 · Hoge et al. · 2014 [cited by applicant]
US 20140275229A1 · Bancel et al. · 2014 [cited by applicant]
US 20140294937A1 · MacLachlan et al. · 2014 [cited by applicant]
US 20140343129A1 · de Fougerolles et al. · 2014 [cited by applicant]
US 20150005372A1 · Hoge et al. · 2015 [cited by applicant]
US 20150017211A1 · de Fougerolles et al. · 2015 [cited by applicant]
US 20150044277A1 · Bancel et al. · 2015 [cited by applicant]
US 20150050354A1 · Bouchon et al. · 2015 [cited by applicant]
US 20150051268A1 · Bancel et al. · 2015 [cited by applicant]
US 20150056253A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064235A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064236A1 · Bancel et al. · 2015 [cited by applicant]
US 20150064242A1 · Heyes et al. · 2015 [cited by applicant]
US 20150064725A1 · Schrum et al. · 2015 [cited by applicant]
US 20150086614A1 · Bancel et al. · 2015 [cited by applicant]
US 20150110857A1 · DeRosa et al. · 2015 [cited by applicant]
US 20150111248A1 · Bancel et al. · 2015 [cited by applicant]
US 20150111945A1 · Geisbert et al. · 2015 [cited by applicant]
US 20150166465A1 · Chen et al. · 2015 [cited by applicant]
US 20150190515A1 · Manoharan et al. · 2015 [cited by applicant]
US 20150265708A1 · Manoharan et al. · 2015 [cited by applicant]
US 20150315541A1 · Bancel et al. · 2015 [cited by applicant]
US 20150315584A1 · MacDonald et al. · 2015 [cited by applicant]
US 20150366997A1 · Guild et al. · 2015 [cited by applicant]
US 20160038432A1 · Derosa et al. · 2016 [cited by applicant]
US 20160095924A1 · Hope et al. · 2016 [cited by applicant]
US 20160114011A1 · Bancel et al. · 2016 [cited by applicant]
US 20160115477A1 · MacLachlan et al. · 2016 [cited by applicant]
US 20160115483A1 · MacLachlan et al. · 2016 [cited by applicant]
US 20160136236A1 · Hoge et al. · 2016 [cited by applicant]
US 20160151284A1 · Heyes et al. · 2016 [cited by applicant]
US 20160158385A1 · Bancel et al. · 2016 [cited by applicant]
US 20160193299A1 · de Fougerolles et al. · 2016 [cited by applicant]
US 20160194368A1 · Hoge et al. · 2016 [cited by applicant]
US 20160194625A1 · Hoge et al. · 2016 [cited by applicant]
US 20160213785A1 · Monoharan et al. · 2016 [cited by applicant]
US 20160237108A1 · Fraley et al. · 2016 [cited by applicant]
US 20160237134A1 · Hoge et al. · 2016 [cited by applicant]
US 20190029959A1 · Costa et al. · 2019 [cited by applicant]
US 20220110884A1 · Karve et al. · 2022 [cited by applicant]
CA 2807552 · 2012 [cited by applicant]
CA 3063531 · 2018 [cited by examiner]
EP 1519714 · 2010 [cited by applicant]
EP 2449106 · 2012 [cited by applicant]
EP 2338478 · 2013 [cited by applicant]
EP 2823809 · 2015 [cited by applicant]
EP 3020701 · 2016 [cited by applicant]
JP 09170568 · 1997 [cited by applicant]
JP 2007051551 · 2007 [cited by applicant]
WO WO1989000826 · 1989 [cited by applicant]
WO WO1993003709 · 1993 [cited by applicant]
WO WO2000029103 · 2000 [cited by applicant]
WO WO2001005373 · 2001 [cited by applicant]
WO WO2004002453 · 2004 [cited by applicant]
WO WO2005026372 · 2005 [cited by applicant]
WO WO2005121348 · 2005 [cited by applicant]
WO WO2009127060 · 2009 [cited by applicant]
WO WO2010042877 · 2010 [cited by applicant]
WO WO2011068810 · 2011 [cited by applicant]
WO WO2011141705 · 2011 [cited by applicant]
WO WO2012019168 · 2012 [cited by applicant]
WO WO2012135805 · 2012 [cited by applicant]
WO WO2012170930 · 2012 [cited by applicant]
WO WO2013006825 · 2013 [cited by applicant]
WO WO2013039857 · 2013 [cited by applicant]
WO WO2013039861 · 2013 [cited by applicant]
WO WO2013090186 · 2013 [cited by applicant]
WO WO2013093648 · 2013 [cited by applicant]
WO WO2013101690 · 2013 [cited by applicant]
WO WO2013126803 · 2013 [cited by applicant]
WO WO2013130161 · 2013 [cited by applicant]
WO WO2013151663 · 2013 [cited by applicant]
WO WO2013151664 · 2013 [cited by applicant]
WO WO2013151666 · 2013 [cited by applicant]
WO WO2013151667 · 2013 [cited by applicant]
WO WO2013151668 · 2013 [cited by applicant]
WO WO2013151670 · 2013 [cited by applicant]
WO WO2013151671 · 2013 [cited by applicant]
WO WO2013151672 · 2013 [cited by applicant]
WO WO2013151736 · 2013 [cited by applicant]
WO WO2014089486 · 2014 [cited by applicant]
WO WO2014113089 · 2014 [cited by applicant]
WO WO2014144039 · 2014 [cited by applicant]
WO WO2014144711 · 2014 [cited by applicant]
WO WO2014144767 · 2014 [cited by applicant]
WO WO2014152027 · 2014 [cited by applicant]
WO WO2014152030 · 2014 [cited by applicant]
WO WO2014152031 · 2014 [cited by applicant]
WO WO2014152211 · 2014 [cited by applicant]
WO WO2014152540 · 2014 [cited by applicant]
WO WO2014158795 · 2014 [cited by applicant]
WO WO2014159813 · 2014 [cited by applicant]
WO WO2015006747 · 2015 [cited by applicant]
WO WO2015048744 · 2015 [cited by applicant]
WO WO2015051169 · 2015 [cited by applicant]
WO WO2015051173 · 2015 [cited by applicant]
WO WO2015058069 · 2015 [cited by applicant]
WO WO2015128030 · 2015 [cited by applicant]
WO WO2015011633 · 2016 [cited by applicant]
WO WO2016004318 · 2016 [cited by applicant]
WO WO2016054421 · 2016 [cited by applicant]
WO WO2016071857 · 2016 [cited by applicant]
WO WO2016077123 · 2016 [cited by applicant]
WO WO2016077125 · 2016 [cited by applicant]
WO WO2016118724 · 2016 [cited by applicant]
WO WO2016118725 · 2016 [cited by applicant]
WO WO2018213476 · 2018 [cited by applicant]
WO WO2019191780 · 2019 [cited by applicant]
WO WO2019207060 · 2019 [cited by applicant]
WO WO2020047061 · 2020 [cited by applicant]
WO WO2020160397 · 2020 [cited by applicant]
WO WO2020232276 · 2020 [cited by applicant]
Alton et al., “A randomised, double-blind, placebo-controlled trial of repeated nebulisation of non-viral cystic fibrosis transmembrane conductance regulator (CFTR) gene therapy in patients with cystic fibrosis,” Effica… [cited by applicant]
Arteta et al., “Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles,” PNAS, 115(15), E3351-E3360 (2018). [cited by applicant]
Avnir et al. “Amphipathic weak acid glucocorticoid prodrugs remote-loaded into sterically stabilized nanoliposomes evaluated in arthritic rats and in a Beagle dog: a novel approach to treating autoimmune arthritis.” Art… [cited by applicant]
Bartoszewski et al., “A Synonymous Single Nucleotide Polymorphism in ΔF508 [cited by applicant]
Belliveau et al. “Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.” Molecular Therapy-Nucleic Acids 2012 1,e37:1-9 (2012). [cited by applicant]
Buyens et al. “Liposome based systems for systemic siRNA delivery: stability in blood sets the requirements for optimal carrier design.” Journal of Controlled Release, 2012 158:362-370. [cited by applicant]
Fenske et al. “Liposomal nanomedicines.” Expert Opinion on Drug Delivery 2008 5(1):25-44. [cited by applicant]
Fritze et al. “Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient.” Biochimica et Biophysica Acta 2006 17 58: 1633-1640 (Year: 2006). [cited by applicant]
GenBank: AAA16036.1, Carboxylesterase [ [cited by applicant]
GenBank: AAA29804.1, Luciferase [ [cited by applicant]
GenBank: AAA39865.1, Ornithine Transcarbamylase [ [cited by applicant]
GenBank: AAC13657.1, Cystic Fibrosis Transmembrane Conductance Regulator [ [cited by applicant]
GIBCO OPTIMEM I product information (2001). [cited by applicant]
Gjetting et al. “A simple protocol for preparation of a liposomal vesicle with encapsulated plasmid DNA that mediate high accumulation and reporter gene activity in tumor tissue.” Results in Pharma Sciences, 2011 1 :49-… [cited by applicant]
Harvard Apparatus Dual Syringe Pump Model 33 User's Manual (1996). [cited by applicant]
Harvard Apparatus Syringe Pump Series User Manual, http://www.harvardapparatus.com/media/harvard/pdf/551689_Pump_975_Manual.pdf retrieved Dec. 27, 2019. [cited by applicant]
Hayes et al. “Genospheres: self-assembling nucleic acid-lipid nanoparticles suitable for targeted gene delivery.” Gene Therapy, 2006 13:646-651. [cited by applicant]
Hood et al. “Microfluidic remote loading for rapid single-step liposomal drug preparation.” Lab on a Chip, 2014 14:3359-3367. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/054527, 15 pages, dated Jan. 25, 2022. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2021/054532, 14 pages, dated Jan. 22, 2022. [cited by applicant]
Isele et al., “Large-Scale Production of Liposomes Containing Monomeric Zinc Phthalocyanine by Controlled Dilution of Organic Solvents,” Journal of Pharmaceutical Sciences, vol. 83, Issue 11, pp. 1608-1616, Nov. 1994. [cited by applicant]
Jeffs et al., “A scalable, extrusion-free method for efficient liposomal encapsulation of plasmid DNA,” Pharm. Res. 22(3): 362-372, (2005). [cited by applicant]
Johnston et al., “Prolonged Pulseless Perfusion in Unanesthetized Claves,” JAMA Surgery 111(11): 1225-30 (1976) Abstract only. [cited by applicant]
Kauffman et al. “Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs.” Nano Letters, 2015 15(11):7300-7306. [cited by applicant]
Khurana et al., “Lipoplexes versus nanoparticles: pDNA/siRNA delivery,” Drug Delivery, 20:2, 57-64 (2013). [cited by applicant]
Kubota et al. “Effect of the nanoformulation of siRNA-lipid assemblies on their cellular uptake and immune stimulation.” International Journal of Nanomedicine, 12:5121-5133 (2017). [cited by applicant]
Leung et al. “Lipid Nanoparticles Containing siRNA Synthesized by Microfluidic Mixing Exhibit an Electron-Dense Nanostructured Core.” Journal of Physical Chemistry 2012 116: 18440-18450. [cited by applicant]
Martinon et al. “Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA.” European Journal of Immunology, 1993 23:1719-1722. [cited by applicant]
Malone et al., “Cationic liposome-mediated RNA transfection” PNAS 86:6077-6081, (1989). [cited by applicant]
Maurer et al., “Spontaneous Entrapment of Polynucleotides upon Electrostatic Interaction with Ethanol-Destabilized Cationic Liposomes” Biophys. J. 80:2310-2326, (2001). [cited by applicant]
Michelon et al., “High Throughput Continuous Production of Liposomes Using Hydrodynamic Flow-Focusing Microfliudic Devices,” Colloids and Surfaces B: Biointerfaces 156: 349-357, (2017). [cited by applicant]
Perez et al., “Formulation Strategies, Characterization, and In Vitro Evaluation of Lecithin-Based Nanoparticles for siRNA Delivery”. Journal of Drug Delivery, vol. 2012, Article ID 986265, 9 pages (2012). [cited by applicant]
Porteous et al. “Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis” Gene Therapy 4:210-218, (1997). [cited by applicant]
Pradhan et al., “A Facile Microfluidic Method for Production of Liposomes,” Anticancer Research 28, pp. 943-948, 2008. [cited by applicant]
Remaut et al., Influence of plasmid DNA topology on the transfection properties of DOTAP/DOPE lipoplexes. Journal of Controlled Release, 115: 335-343 (2006). [cited by applicant]
Saravolac et al., “Encapsulation of Plasmid DNA in Stabilized Plasmid—Lipid Particles Composed of Different Cationic Lipid Concentration for Optimal Transfection Activity” J Drug Targeting 7(6): 423-437, (2000). [cited by applicant]
Semple et al., “Rational Design of Cationic Lipids for siRNA Delivery,” Nature Biotechnology, vol. 28, No. 2, pp. 172-176, Feb. 2010. [cited by applicant]
Trevisan et al. Non-Viral Gene Therapy, pp. 267-292, 2011, Prof. Xubo uan (editor), InTech (publisher), ISBN 978-953-307-538-9. [cited by applicant]
VerderGear Mag-Drive External Gear Pump Product Overview, https://www.verderliquids.com/fileadmin/user_upload/Test/Verdergear_brochure/Verdergear_INT_Brochure.pdf, retrieved Dec. 30, 2019. [cited by applicant]
Wan et al. “Lipid nanoparticle delivery systems for siRNA-based therapeutics.” Drug Delivery and Translational Research, 2014 4:74-83. [cited by applicant]
Wang et al.“Bone-Targeted 2,6,9-Trisubstituted Purines: Novel Inhibitors of Src Tyrosine Kinase for the Treatment of Bone Diseases.” Artificial Cells, Blood Substitutes, and Technology, 2003 31 (3):303-312. [cited by applicant]
Wang et al. “Systemic delivery of modified mRNA encoding herpes simplex virus 1 thymidine kinase for targeted cancer gene therapy.” Molecular Therapy, 2013 21(2):358-367. [cited by applicant]
Zhao et al., N/P Ratio Significantly Influences the Transfection Efficiency and Cytotoxicity of a Polyethylenimine/Chitosan/DNA Complex. Bio. Pharm. Bull. 32(4): 706-710 (2009). [cited by applicant]
Zohra et al., “Effective Delivery with Enhanced Translational Activity Synergistically Accelerates mRNA-based transfection,” Biochemical and Biophysical Research Communications 358 (2007), pp. 373-378. [cited by applicant]
Chen et al., “Scaffold-mediated delivery for non-viral mRNA vaccines”, Gene Therapy, 2018, 25: 556-567. [cited by applicant]
Evers et al., “State-of-the-Art Design and Rapid-Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery”, Small Methods, Sep. 11, 2018, 2(9): 1700375. [cited by applicant]
Ramaswamy et al., “Systemic delivery of factor IX messenger RNA for protein replacement therapy”, PNAS, Mar. 7, 2017, 114(10): E1941-E1950, ePublished Feb. 15, 2017. [cited by applicant]
Udhayakumar et al., “Arginine-rich peptide-based mRNA nanocomplexes efficiently instigate cytotoxic T cell immunity dependent on the amphipathic organization of the peptide”, Adv Healthcare Mater., 2017, 6(13): 1-13. [cited by applicant]
Van Tendeloo et al., “Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen … [cited by applicant]
Oberli et al., “Lipid Nanoparticle Assisted mRNA Delivery for Potent Cancer Immunotherapy”, Nano Lett., Nov. 23, 2017, 17(3): 1326-1335. [cited by applicant]